ATE456367T1 - Proteinkinase c inhibitoren - Google Patents

Proteinkinase c inhibitoren

Info

Publication number
ATE456367T1
ATE456367T1 AT04102054T AT04102054T ATE456367T1 AT E456367 T1 ATE456367 T1 AT E456367T1 AT 04102054 T AT04102054 T AT 04102054T AT 04102054 T AT04102054 T AT 04102054T AT E456367 T1 ATE456367 T1 AT E456367T1
Authority
AT
Austria
Prior art keywords
beta
protein kinase
inhibitors
isozyme
present
Prior art date
Application number
AT04102054T
Other languages
English (en)
Inventor
William Francis Heath Junior Heath
John Hampton Mcdonald Iii
Michael Paal
Gerd Ruhter
Schotten Theo
Wolfgang Stenzel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/324,948 external-priority patent/US5545636A/en
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE456367T1 publication Critical patent/ATE456367T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT04102054T 1993-12-23 1994-12-14 Proteinkinase c inhibitoren ATE456367T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US17374193A 1993-12-23 1993-12-23
US08/324,948 US5545636A (en) 1993-12-23 1994-10-18 Protein kinase C inhibitors

Publications (1)

Publication Number Publication Date
ATE456367T1 true ATE456367T1 (de) 2010-02-15

Family

ID=26869484

Family Applications (2)

Application Number Title Priority Date Filing Date
AT95904892T ATE290378T1 (de) 1993-12-23 1994-12-14 Proteinkinase c-inhibitoren
AT04102054T ATE456367T1 (de) 1993-12-23 1994-12-14 Proteinkinase c inhibitoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT95904892T ATE290378T1 (de) 1993-12-23 1994-12-14 Proteinkinase c-inhibitoren

Country Status (12)

Country Link
US (3) US5661173A (de)
EP (2) EP1449529B1 (de)
JP (4) JP3998261B2 (de)
AT (2) ATE290378T1 (de)
AU (1) AU1339895A (de)
CA (1) CA2179650C (de)
DE (1) DE69434294T2 (de)
DK (1) DK0817627T3 (de)
ES (1) ES2236702T3 (de)
PT (1) PT817627E (de)
SI (1) SI0817627T1 (de)
WO (1) WO1995017182A1 (de)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20000064764A (ko) * 1996-03-20 2000-11-06 피터지.스트링거 인돌릴말레이미드의제조방법
US6232299B1 (en) * 1996-05-01 2001-05-15 Eli Lilly And Company Use of protein kinase C inhibitors to enhance the clinical efficacy of oncolytic agents and radiation therapy
SE9603284D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603283D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
SE9603285D0 (sv) * 1996-09-10 1996-09-10 Astra Ab New compounds
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
US5859261A (en) * 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
AR017200A1 (es) 1997-12-23 2001-08-22 Astrazeneca Ab Compuestos inhibidores de la proteina cinasa c, sales farmaceuticamente aceptables de los mismos, formulaciones farmaceuitcas que los comprenden, usode las mismas y proceso para la sintesis de dichos compuestos
SE9800835D0 (sv) 1998-03-13 1998-03-13 Astra Ab New Compounds
HRP20000585B1 (en) * 1998-03-17 2009-02-28 F. Hoffmann - La Roche Ag Substituted bisindolymaleimides for the inhibition of cell proliferation
DE19838506C2 (de) * 1998-05-04 2000-08-31 Asta Medica Ag Indolderivate und deren Verwendung zur Behandlung von malignen und anderen, auf pathologischen Zellproliferationen beruhenden Erkrankungen
ES2190221T3 (es) * 1998-05-04 2003-07-16 Zentaris Ag Derivados de indol y su uso para el tratamiento de enfermedades malignas y otras, que se basan en proliferaciones celulares patologicas.
US6127401A (en) 1998-06-05 2000-10-03 Cephalon, Inc. Bridged indenopyrrolocarbazoles
US6013646A (en) 1998-07-02 2000-01-11 Bayer Corporation Indolocarbazole derivatives useful for the treatment of neurodegenerative diseases and cancer
US6841567B1 (en) * 1999-02-12 2005-01-11 Cephalon, Inc. Cyclic substituted fused pyrrolocarbazoles and isoindolones
US6492406B1 (en) 1999-05-21 2002-12-10 Astrazeneca Ab Pharmaceutically active compounds
US6284783B1 (en) 1999-06-09 2001-09-04 The Uab Research Foundation Use of bisindolylmaleimide compounds to induce Fas-mediated apoptosis
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
EP1106605A4 (de) * 1999-06-24 2005-12-07 Toray Industries Antagonisten des andrenergen-alpha1b-rezeptors
US6399780B1 (en) * 1999-08-20 2002-06-04 Cephalon, Inc. Isomeric fused pyrrolocarbazoles and isoindolones
DE60010934T2 (de) * 1999-12-16 2005-05-19 Eli Lilly And Co., Indianapolis Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
US6867198B2 (en) 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
US6743785B2 (en) 1999-12-16 2004-06-01 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
CA2408747C (en) * 2000-05-11 2011-04-05 Consejo Superior Investigaciones Cientificas Heterocyclic inhibitors of glycogen synthase kinase gsk-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
AU2001271257A1 (en) * 2000-06-29 2002-01-14 Eli Lilly And Company Use of a protein kinase c inhibitor to enhance the clinical efficacy of anti-neoplastic chemotherapeutic agents and radiation therapy
WO2002002116A2 (en) * 2000-06-29 2002-01-10 Eli Lilly And Company Therapeutic treatment of cancer with a protein kinase c inhibitor
KR20040016828A (ko) 2000-12-08 2004-02-25 오르토-맥네일 파마슈티칼, 인코퍼레이티드 키나제 저해제로서 인다졸릴-치환된 피롤린 화합물
RU2004135382A (ru) 2002-06-05 2005-06-27 Янссен Фармацевтика Н.В. (Be) Замещенные пирролины в качестве ингибиторов киназы
JP2005531607A (ja) 2002-06-05 2005-10-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ キナーゼ阻害剤として置換ピロリン
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
DE10244453A1 (de) 2002-09-24 2004-04-01 Phenomiques Gmbh Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
DE602004014965D1 (de) * 2003-10-24 2008-08-21 Lilly Co Eli Bisindolylmaleimid zur behandlung von prostatakrebs und akt-vermittelten erkrankungen
GB0329667D0 (en) 2003-12-22 2004-01-28 King S College London Core 2 GlcNAc-T inhibitor
US20080182801A1 (en) 2003-12-22 2008-07-31 Btg International Limited Core 2 glcnac-t inhibitors
GB0513881D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors III
CA2571421A1 (en) 2004-06-24 2006-01-05 Nicholas Valiante Compounds for immunopotentiation
DK1846406T5 (da) 2005-02-09 2011-10-31 Arqule Inc Maleimidderivater, farmaceutiske sammensætninger og fremgangsmåder til behandling af cancer
WO2006108270A1 (en) * 2005-04-11 2006-10-19 Pharmagap Inc. Inhibitors of protein kinases and uses thereof
GB0513888D0 (en) 2005-07-06 2005-08-10 Btg Int Ltd Core 2 GLCNAC-T Inhibitors II
PL1904482T3 (pl) * 2005-07-11 2011-06-30 Novartis Ag Pochodne indolilomaleimidowe
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
GB0605691D0 (en) * 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
CN101801937A (zh) 2007-06-22 2010-08-11 艾科尔公司 喹唑啉酮化合物及其使用方法
JP5490688B2 (ja) 2007-06-22 2014-05-14 アークル インコーポレイテッド 癌の治療のためのインドリルピロリジン
CA2690799C (en) 2007-06-22 2015-06-16 Arqule, Inc. Pyrrolidinone, pyrrolidine-2,5-dione, pyrrolidine and thiosuccinimide derivatives, compositions and methods for treatment of cancer
KR20100093129A (ko) 2007-12-20 2010-08-24 노파르티스 아게 Ｐｉ ３ 키나제 억제제로서 사용되는 티아졸 유도체
WO2010019225A1 (en) * 2008-08-15 2010-02-18 Robert Shorr Pharmaceutical composition
CA2746085A1 (en) 2008-12-15 2010-07-01 Eli Lilly And Company Enzastaurin for the treatment of cancer
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
US8748428B2 (en) 2010-03-30 2014-06-10 Novartis Ag Use of a PKC inhibitor
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
CA2825605C (en) 2011-01-31 2019-05-07 Novartis Ag Heterocyclic derivatives
EP2567959B1 (de) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamid-derivate als kinaseinhibitoren
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8846712B2 (en) 2011-09-12 2014-09-30 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
SMT201700009T1 (it) 2012-03-16 2017-03-08 Vitae Pharmaceuticals Inc Modulatori del recettore x del fegato
SG11201405328SA (en) 2012-03-16 2014-11-27 Vitae Pharmaceuticals Inc Liver x receptor modulators
WO2013167403A1 (en) 2012-05-09 2013-11-14 Sanofi Substituted 6-(4-hydroxy-phenyl)-1h-pyrazolo[3,4-b]pyridine derivatives as kinase inhibitors
SG11201406550QA (en) 2012-05-16 2014-11-27 Novartis Ag Dosage regimen for a pi-3 kinase inhibitor
US9446043B2 (en) 2012-11-29 2016-09-20 Novartis Ag Pharmaceutical combinations
WO2014174478A1 (en) 2013-04-26 2014-10-30 Novartis Ag Pharmaceutical combinations of a pkc inhibitor and a c-met receptor tyrosine kinase inhibitor
KR20160095035A (ko) 2013-12-06 2016-08-10 노파르티스 아게 알파-이소형 선택성 포스파티딜이노시톨 3-키나제 억제제를 위한 투여 요법
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
CN104398508B (zh) * 2014-11-28 2017-06-13 上海交通大学 双吲哚马来酰亚胺衍生物在制备治疗慢性粒细胞白血病药物中的应用
KR20180073674A (ko) 2015-11-02 2018-07-02 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제에 대한 투여 요법
EP4455145A3 (de) * 2015-12-02 2025-03-12 Astraea Therapeutics, LLC Piperidinyl-nociceptin-rezeptorverbindungen
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
CN110526903B (zh) * 2016-06-01 2021-12-10 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
CN110218206B (zh) * 2016-06-01 2022-03-04 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途
JOP20190025A1 (ar) 2016-09-01 2019-02-19 Denovo Biopharma Llc طرق وتركيبة لتوقع نشاط إنزاستورين
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
WO2019000224A1 (zh) * 2017-06-27 2019-01-03 中国海洋大学 双吲哚马来酰亚胺衍生物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4808613A (en) * 1986-11-21 1989-02-28 Bristol-Myers Company Rebeccamycin derivative containing pharmaceutical composition
US4785085A (en) * 1986-11-21 1988-11-15 Bristol-Myers Company Rebeccamycin analogs
US4923986A (en) * 1987-03-09 1990-05-08 Kyowa Hakko Kogyo Co., Ltd. Derivatives of physiologically active substance K-252
DE3803620A1 (de) * 1988-02-06 1989-08-17 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und diese enthaltende arzneimittel
SK75289A3 (en) * 1988-02-10 1998-05-06 Hoffmann La Roche Substituted pyrroles, their use for producing a drug, and the drug on their base
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
DE3914764A1 (de) * 1989-05-05 1990-11-08 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
US5380746A (en) * 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
IL94274A0 (en) 1989-05-05 1991-03-10 Goedecke Ag Maleinimide derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
DE3942991A1 (de) * 1989-12-27 1991-07-04 Goedecke Ag Maleinimid-derivate und deren verwendung als arzneimittel
DE3942296A1 (de) * 1989-12-21 1991-06-27 Goedecke Ag Indolocarbazol-derivate, verfahren zu deren herstellung und deren verwendung
DE4005969A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005970A1 (de) * 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
CA2046801C (en) * 1990-08-07 2002-02-26 Peter D. Davis Substituted pyrroles
US5292747A (en) * 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
EP0580609A1 (de) * 1991-03-22 1994-02-02 Xenova Limited Pharmazeutische xanthonderivate
GB9123396D0 (en) * 1991-11-04 1991-12-18 Hoffmann La Roche A process for the manufacture of substituted maleimides
AU3761393A (en) * 1992-03-20 1993-10-21 Wellcome Foundation Limited, The Indole derivatives with antiviral activity
US5461146A (en) * 1992-07-24 1995-10-24 Cephalon, Inc. Selected protein kinase inhibitors for the treatment of neurological disorders
DE4243321A1 (de) * 1992-12-21 1994-06-23 Goedecke Ag Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
AU678435B2 (en) * 1993-05-10 1997-05-29 F. Hoffmann-La Roche Ag Substituted pyrroles
US5481003A (en) * 1994-06-22 1996-01-02 Eli Lilly And Company Protein kinase C inhibitors

Also Published As

Publication number Publication date
EP1449529B1 (de) 2010-01-27
JP3998261B2 (ja) 2007-10-24
DE69434294D1 (de) 2005-04-14
ES2236702T3 (es) 2005-07-16
JP4365803B2 (ja) 2009-11-18
EP1449529A1 (de) 2004-08-25
JP4490400B2 (ja) 2010-06-23
PT817627E (pt) 2005-07-29
CA2179650C (en) 2007-10-30
EP0817627B1 (de) 2005-03-09
JP4369397B2 (ja) 2009-11-18
JP2005225896A (ja) 2005-08-25
SI0817627T1 (de) 2005-08-31
JP2006316068A (ja) 2006-11-24
AU1339895A (en) 1995-07-10
HK1008183A1 (en) 1999-05-07
JPH09507066A (ja) 1997-07-15
ATE290378T1 (de) 2005-03-15
JP2005225895A (ja) 2005-08-25
CA2179650A1 (en) 1995-06-29
EP0817627A1 (de) 1998-01-14
DE69434294T2 (de) 2005-12-29
EP0817627A4 (de) 2002-07-17
US5672618A (en) 1997-09-30
DK0817627T3 (da) 2005-06-06
WO1995017182A1 (en) 1995-06-29
US5668152A (en) 1997-09-16
US5661173A (en) 1997-08-26

Similar Documents

Publication Publication Date Title
DE69434294D1 (de) Proteinkinase c-inhibitoren
DK0766682T3 (da) Proteinkinase-C-inhibitorer
CA2376596A1 (en) Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
EP1040827A3 (de) Verwendung von 3,4-dihydroxy-2-hydroxymethylpyrrolidin zur behandlung von diabetes
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
NO900853D0 (no) Slitebane for kjoeretoeydekk med midtre partier forsynt medskraa innsnitt.
NZ324921A (en) Cathepsin K crystal structure and methods of identifying inhibitors of this protease
AU2002366641A1 (en) Methods for inhibiting ocular processes
HRP950288A2 (en) Oxalylamino-benzofuran- and benzothienyl-derivatives
WO2005044093A3 (en) Delta-9- the treatment of multiple sclerosis
FI941411L (fi) Vaahdotuskammio, jossa on injektori
IT1240486B (it) Procedimento di ammollo enzimatico per pelli e pellami.
ATE206875T1 (de) Methode zur verbesserung der fortpflanzungsfähigkeit von ebern durch verwendung eines speziellen futters für zuchteber
WO1993015112A3 (en) COMPOUNDS AND METHODS FOR INHIBITING β-PROTEIN FUNCTION
TR28218A (tr) Boyama proseslerinde karbondioksit kullanarak ph degerinin ayarlanmasi.
IL142220A0 (en) Method of treating viral hemorrhagic fever
DE3861462D1 (de) Gasfeuerzeugstruktur, geeignet zur andrueckmontage seiner hauptteile.
WO2001087239A3 (en) Methods of affecting laminin 5 processing
EP0972012A4 (de) Immunsuppression
BR9915572A (pt) Processo de tratamento de doença de célula falciforme e talassemia
IL142255A0 (en) Method of treating heparin-induced thrombocytopenia
BR9801691B1 (pt) processo de desaromatização de hidrocarbonetos por adsorção.
WO2000058506A3 (en) Susceptibility to psoriasis
WO2004017909A3 (en) Methods of reducing ischemic injury
EP0646651A3 (de) Verfahren zur Verbesserung der Lederbehandlung.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties